MedTrace Logo

Investigation and Modulation of the Mu-opioid Mechanisms in TMD (in Vivo)

NCT03724032 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-06-15

Study results available
· View outcomes & findings →

Summary

In this study, this team of researchers will investigate the impact of chronic temporomandibular disorder suffering on the endogenous μ-opioid system in vivo, arguably one of the principal endogenous pain modulatory systems in the brain, and its modulation by 10 daily sessions of primary motor cortex stimulation using high-definition transcranial direct current stimulation (HD-tDCS).

Conditions

  • Temporomandibular Disorder

Interventions

DEVICE

HD-tDCS*

Non-invasive brain stimulation (active protocol)

DEVICE

Sham HD-tDCS*

Non-invasive brain stimulation (sham protocol)

Sponsors & Collaborators

  • National Institute of Dental and Craniofacial Research (NIDCR)

    collaborator NIH

  • University of Michigan

    lead OTHER

Principal Investigators

  • Alexandre F DaSilva, DDS, DMedSc · University of Michigan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-13
Primary Completion
2022-01-17
Completion
2022-01-17
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03724032 on ClinicalTrials.gov